<DOC>
	<DOCNO>NCT02080221</DOCNO>
	<brief_summary>A standard treatment cancer call FOLFIRINOX ( utilizes FDA approve chemotherapy drug fluorouracil , leucovorin , oxaliplatin irinotecan ) . In study receive chemotherapy treatment FOLFOX-A ( fluorouracil , oxaliplatin , leucovorin Abraxane ® ) substitute irinotecan FDA approve chemotherapy drug Abraxane ® . Even though Abraxane FDA approve pancreatic cancer , combination Abraxane 3 drug investigate . Your doctor study activity side effect FOLFOX-A advance ( metastatic ) pancreatic cancer .</brief_summary>
	<brief_title>BrUOG 292 : FOLFOX-A For Metastatic Pancreatic Cancer : A Phase II Brown University Oncology Research Group Trial</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1 . Pathologically cytological confirm pancreatic ductal adenocarcinoma . Patients pathology cytology show carcinoma pancreas adenosquamous pancreas also eligible . 2 . Metastatic advance disease . 3 . No prior chemotherapy pancreatic cancer 4 . No major surgery within 3 week start study treatment . Patients must recover side effect major surgery start study treatment . For question surgery deem `` major , '' definition surgeon use clarification . Laparoscopy central venous catheter placement consider major surgery . 5 . No prior invasive malignancy within prior two year . However , patient early stage malignancy expect require treatment next 2 year ( early stage , resect breast cancer asymptomatic prostate cancer ) eligible . 6 . ECOG performance status 0 1 . 7 . Age ≥ 18 8 . Not pregnant nursing . Women child bear potential must negative serum urine pregnancy test ( minimum sensitivity 25 IU/L equivalent unit HCG ) within 7 day prior begin treatment . Postmenopausal woman ( surgical menopause lack menses &gt; 12 month ) need pregnancy test , please document status . 9 . Women childbearing potential sexually active male must use effective contraception method treatment three month complete treatment . Documentation discuss require . 10 . Required Initial Laboratory Values : Neutrophils ≥ 1,500/mm3 Platelet count ≥ 100,000/mm3 Creatinine ≤ 1.5 mg/dL creatinine clearance ≥ 60 mL/min Total bilirubin ≤ 1.25 x ULN AST ( SGOT ) &amp; ALT ( SGPT ) ≤ 2.5 x ULN ( patient liver metastasis , AST &amp; ALT &lt; 5xULN ) Alkaline phosphatase &lt; 2.5xULN , unless bone metastasis present absence liver metastasis 1 . Patients know brain metastasis 2 . Prior hypersensitivity Oxaliplatin Abraxane ® investigator opinion would put patient risk reexposed 3 . Preexisting neuropathy 4 . Patients serious medical risk factor involve major organ system investigator considers unsafe patient receive FOLFOXA 5 . Patients unstable biliary stent plastic stent . Information type stent require registration . 6 . Patients active infection fever ( patient antibiotic infection patient get cold seasonal virus exclude ) , know historical active infection HIV , hepatitis B , hepatitis C. 7 . Patients sepsis pneumonitis . 8 . Patients history interstitial lung disease , history slowly progressive dyspnea unproductive cough , sarcoidosis , silicosis , idiopathic pulmonary fibrosis , pulmonary hypersensitivity pneumonitis multiple allergy investigator 's opinion would put patient increase risk . 10 . Uncontrolled diabetes . If patient diabetes , confirmation status ( control uncontrolled ) require registration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>metastatic pancreatic cancer</keyword>
	<keyword>pancreatic cancer</keyword>
	<keyword>metastatic</keyword>
</DOC>